ProSanos Corporation Announces the Release of CLÆRITY^® for the Evaluation of Drug Safety (6/19/2007)
CLÆRITY^® can be used to explore questions about the safety of a particular drug, class of drugs, or therapeutic area
Harrisburg, PA - June 19, 2007. ProSanos Corporation, specializing in the capture, integration, and analysis of healthcare-related data, has announced the launch of CLÆRITY, a next-generation software product that can be used to explore questions about the safety of a particular drug, class of drugs, or therapeutic area.

ProSanos Corporation Joins BioIT Alliance (11/14/2006)
ProSanos Corporation, specialists in the capture, integration, and analysis of healthcare-related data, is pleased to announce that it has joined Microsoft Corporation and an array of other leading organizations in a collaborative effort known as the BioIT Alliance.

Prosanos Corporation and France's Groupe MAPI Announce Strategic Partnership (7/26/2006)
ProSanos Corporation, specialists in the capture, integration, and analysis of healthcare-related data, and Groupe MAPI, an organization dedicated to providing the expertise needed to fully evaluate a drug’s properties and qualities, announce today the formation of a strategic corporate partnership which includes an investment in ProSanos by the MAPI Groupe.

ProSanos Corporation Awarded PhRMA Grant to Study Drug Safety (6/6/2006)
Sponsors Hope Effort to Bolster Monitoring and Detection of Adverse Events Will Lead to Improved Patient Outcomes and Enhanced Decision-Making for Drug Developers

ProSanos Receives Grant from the Department of Defense to Develop Pharmacovigilance Tool (1/24/2006)

Summary of Testimony of Caroline J Loew, Ph.D., PhRMA (5/7/2007)
Assessing the Safety of our Nation's Drug Supply Hearing before the Subcommittee on Health, Committee on Energy and Commerce, United States House of Representatives

Keeping Approvals on Track (8/1/2005)
Applied Clinical Trials Article (August 1,2005)
Registries could strengthen the postapproval safety net—critical in the current cautious environment.

Executive Profile: Jonathan Morris (3/21/2005)
San Diego Business Journal (March 21, 2005)
Jonathan Morris’ background as a trauma surgeon probably prepared him well for the many struggles as chief executive officer of Prosanos Corp.

Highlighting ProSanos Product Development (11/30/2004)
BIO WATCH (November 30, 2004)
A profile of ProSanos and its Harrisburg operation in the newsletter of Pennsylvania BIO, which covers Pennsylvania's bioscience industry.

Patient Registries: Observations of the Real World (8/1/2004)
PharmaVOICE (August, 2004)
ProSanos CEO Jonathan Morris is featured in this article about the value of registries to pharmaceutical companies. (1MB PDF)

ProSanos VP of Research, Alan Hochberg, Appointed to Chair DIA SIAC (6/19/2007)
Alan Hochberg, ProSanos’ Vice President of Research was recently elected as the new North American chair for the Drug Information Association’s Statistics SIAC.

Joachim Schupp New ProSanos VP (10/1/2004)

Russell Ellison Joins ProSanos Board (9/14/2004)

Myra Williams, Michael Lack Join ProSanos Board (12/2/2003)

ProSanos Establishes Central Pennsylvania Office; Wins Grant (4/29/2003)

Using Data Mining to Predict Safety Actions from FDA Adverse Event Reporting System Data
by Hochberg, Alan M, Reisinger, Stephanie J, Pearson, Ronald K, O'Hara, Donald J, Hall, Kevin
Drug Information Journal (September, 2007)
Using AERS data 2-3 years following approval, more than half of FDA actions that aoccurred in the next 2-4 years were predicted by data mining, and more than half of the signals detected by data mining corresponded to an FDA action. An appropriate data mining procedure can yield meaningful safety information, often well in advance of regulatory action.

Data Mining in Pharmacovigilance
International Journal of Pharmaceutical Medicine (September, 2007)
This commentary discusses aspects of computational intensity and cost associated with the application of data mining algorithms (DMAs) to spontaneous reporting system data and inllustrate these wiht a reported drug-event association that was the subject of a recent publication in the journal Drug Safety.

Scientific Software Development is not an Oxymoron
PLOS Computational Biology(9/8/2006)
We see important similarities between the way scientists and software engineers approach and attack problems which may provide a general framework for successful scientific software development. Scientists are taught the scientific method from the time they perform their first experiments. Similarly, software engineers are taught about the software development life cycle before they write their first “if” statement. By understanding similarities between these approaches, we can layer some practical methods from the software development life cycle onto computational biology projects to build a solid foundation for success.

Mycophenolate Mofetil Use is Associated with Decreased Risk of Late Acute Rejection in Adult Liver Transplant Recipients
American Journal of Transplantation (March 2006)
Mycophenolate mofetil (MMF) used in a triple-drug regimen has been shown to decrease acute rejection rates, compared to a double-drug regimen. The impact of MMF on late acute rejection (LAR) episodes has not been well described.

Switching Immunosuppression Medications After Renal Transplantation, A Common Practice
Nephrology Dialysis Transplantation (March 2006)
The rate of change to immunosuppression discharge regimens over time is unknown. We examined the frequency of changes to initial drug treatment regimens and factors associated with a drug change following renal transplantation.